Mount Yale Investment Advisors LLC purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 12,224 shares of the company’s stock, valued at approximately $1,566,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Claraphi Advisory Network LLC acquired a new position in Johnson & Johnson during the 4th quarter worth approximately $1,481,000. Penobscot Investment Management Company Inc. lifted its position in Johnson & Johnson by 0.8% during the 4th quarter. Penobscot Investment Management Company Inc. now owns 75,273 shares of the company’s stock worth $10,517,000 after acquiring an additional 583 shares in the last quarter. Aveo Capital Partners LLC lifted its position in Johnson & Johnson by 10.9% during the 4th quarter. Aveo Capital Partners LLC now owns 5,689 shares of the company’s stock worth $795,000 after acquiring an additional 561 shares in the last quarter. MUFG Securities EMEA plc lifted its position in Johnson & Johnson by 42.5% during the 4th quarter. MUFG Securities EMEA plc now owns 620,000 shares of the company’s stock worth $86,626,000 after acquiring an additional 185,000 shares in the last quarter. Finally, Calton & Associates Inc. acquired a new position in Johnson & Johnson during the 4th quarter worth approximately $1,978,000. Institutional investors own 66.80% of the company’s stock.
In other news, CAO Ronald A. Kapusta sold 7,899 shares of the business’s stock in a transaction that occurred on Friday, September 7th. The stock was sold at an average price of $137.18, for a total value of $1,083,584.82. Following the completion of the sale, the chief accounting officer now directly owns 25,725 shares in the company, valued at approximately $3,528,955.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Michael E. Sneed sold 29,000 shares of the business’s stock in a transaction that occurred on Monday, August 27th. The shares were sold at an average price of $134.80, for a total value of $3,909,200.00. Following the completion of the sale, the chief operating officer now owns 59,124 shares of the company’s stock, valued at $7,969,915.20. The disclosure for this sale can be found here. 0.22% of the stock is currently owned by insiders.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 17th. The company reported $2.10 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.06 by $0.04. Johnson & Johnson had a return on equity of 32.79% and a net margin of 1.70%. The business had revenue of $20.83 billion during the quarter, compared to the consensus estimate of $20.39 billion. During the same period in the previous year, the business earned $1.83 EPS. The business’s quarterly revenue was up 10.6% on a year-over-year basis. equities analysts forecast that Johnson & Johnson will post 8.14 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, September 11th. Stockholders of record on Tuesday, August 28th were issued a $0.90 dividend. The ex-dividend date of this dividend was Monday, August 27th. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.58%. Johnson & Johnson’s dividend payout ratio (DPR) is 49.32%.
Several research firms recently commented on JNJ. Wells Fargo & Co reissued an “outperform” rating and set a $160.00 price target on shares of Johnson & Johnson in a research report on Friday. Credit Suisse Group set a $151.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a report on Tuesday, June 12th. Jefferies Financial Group set a $145.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a report on Sunday, July 15th. ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Saturday, July 28th. Finally, Sanford C. Bernstein began coverage on Johnson & Johnson in a report on Wednesday, June 27th. They set a “market perform” rating and a $129.00 price objective on the stock. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $142.87.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: How to calculate the intrinsic value of a stock
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.